{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:19:23Z","timestamp":1791253163950,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.medmal.2009.05.001","type":"journal-article","created":{"date-parts":[[2009,9,24]],"date-time":"2009-09-24T08:35:13Z","timestamp":1253781313000},"page":"741-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Le traitement de la leishmaniose visc\u00e9rale en Europe en 2009. Place de l\u2019amphot\u00e9ricine B liposomale"],"prefix":"10.1016","volume":"39","author":[{"given":"E.","family":"Rosenthal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Delaunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-Y.","family":"Jeandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pomares-Estran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2009.05.001_bib1","unstructured":"World Health Organization. Leishmaniasis disease burden (web page). 2005 [cited 2005 04\/27\/2005]; Available from: http:\/\/www.who.int\/leishmaniasis\/burden\/en\/."},{"key":"10.1016\/j.medmal.2009.05.001_bib2","series-title":"Tropical infectious diseases: principles, pathogens and practice","first-page":"797","article-title":"Leishmaniasis","author":"Pearson","year":"1999"},{"key":"10.1016\/j.medmal.2009.05.001_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3201\/eid1105.040718","article-title":"Risk factors for kala-azar in Bangladesh","volume":"11","author":"Bern","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib4","first-page":"341","article-title":"Ten years of kala-azar in west Bengal. Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas?","volume":"70","author":"Addy","year":"1992","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.medmal.2009.05.001_bib5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib6","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3201\/eid0912.030178","article-title":"Visceral leishmaniasis treatment, Italy","volume":"9","author":"Gradoni","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib7","first-page":"1666","article-title":"Visceral leishmaniasis and human immunodeficiency virus (HIV) infection in the south of France","volume":"24","author":"Rosenthal","year":"1995","journal-title":"Presse Med"},{"key":"10.1016\/j.medmal.2009.05.001_bib8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/00002030-200106150-00017","article-title":"Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy","volume":"15","author":"Rosenthal","year":"2001","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.medmal.2009.05.001_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1179\/000349803225002606","article-title":"Treatment of leishmaniasis in HIV-positive patients","volume":"97","author":"Laguna","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.medmal.2009.05.001_bib10","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1097\/00002030-200012220-00020","article-title":"Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy","volume":"14","author":"Berenguer","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2009.05.001_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-3156.2001.00778.x","article-title":"Drug resistance in Indian visceral leishmaniasis","volume":"6","author":"Sundar","year":"2001","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.medmal.2009.05.001_bib12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medmal.2009.05.001_bib13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","article-title":"A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study","volume":"17","author":"Thakur","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.05.001_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.medmal.2009.05.001_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.05.001_bib16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jac\/dkh279","article-title":"A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience","volume":"54","author":"Cascio","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.05.001_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1086\/367843","article-title":"Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis","volume":"36","author":"Syriopoulou","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijantimicag.2004.09.011","article-title":"Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?","volume":"25","author":"Kafetzis","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medmal.2009.05.001_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.revmed.2007.03.048","article-title":"Amphot\u00e9ricine B liposomale en cure courte dans le traitement de la leishmaniose visc\u00e9rale m\u00e9diterran\u00e9enne de l\u2019adulte non immunod\u00e9prim\u00e9","volume":"28","author":"Jeandel","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.medmal.2009.05.001_bib21","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial","volume":"87","author":"Davidson","year":"1994","journal-title":"Q J Med"},{"key":"10.1016\/j.medmal.2009.05.001_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.05.001_bib23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"53","author":"L\u00f3pez-V\u00e9lez","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medmal.2009.05.001_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s100960100457","article-title":"Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy","volume":"20","author":"Casado","year":"2001","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4269\/ajtmh.2004.70.298","article-title":"Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy","volume":"70","author":"Mira","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.medmal.2009.05.001_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2009.05.001_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/0022-3859.926","article-title":"Recent understanding in the treatment of visceral leishmaniasis","volume":"49","author":"Rosenthal","year":"2003","journal-title":"J Postgrad Med"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X09001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:06:17Z","timestamp":1759971977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X09001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0399077X09001577"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2009.05.001","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le traitement de la leishmaniose visc\u00e9rale en Europe en 2009. Place de l\u2019amphot\u00e9ricine B liposomale","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2009.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}